{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,6,19]],"date-time":"2025-06-19T04:44:55Z","timestamp":1750308295351,"version":"3.41.0"},"reference-count":28,"publisher":"Public Library of Science (PLoS)","issue":"6","license":[{"start":{"date-parts":[[2025,6,18]],"date-time":"2025-06-18T00:00:00Z","timestamp":1750204800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS One"],"abstract":"<jats:sec id=\"sec001\">\n<jats:title>Objective<\/jats:title>\n<jats:p>To evaluate the cost-effectiveness of two available options for inhaled antibiotic treatment for patients with Bronchiectasis (BE) with <jats:italic>Pseudomonas aeruginosa<\/jats:italic> (PA) infections from the perspective of China\u2019s healthcare system.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec002\">\n<jats:title>Methods<\/jats:title>\n<jats:p>A four-state Markov model was developed over a one-year horizon to simulate the cost-effectiveness of two inhaled antibiotic strategies: Tobramycin inhalation solution (TIS) versus nebulized colistimethate sodium (CMS). The inputs for the model were derived from phase III clinical trials and published literature, with cost data were sourced from public and real-world databases, etc. The incremental cost-effectiveness ratio (ICER) was assessed, setting the willingness-to-pay threshold at one times the per capita GDP of China. Scenario and sensitivity analyses were performed to explore the impact of uncertainties in input parameters.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec003\">\n<jats:title>Results<\/jats:title>\n<jats:p>Over a one-year period, TIS was found to dominate CMS, resulting in a cost saving of CNY 41,109.53 (USD 5,689.27) and an increase of 0.0048 quality-adjusted life years (QALYs) per patient. Sensitivity analyses confirmed the robustness of these findings, which remained consistent under various scenarios.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec004\">\n<jats:title>Conclusions<\/jats:title>\n<jats:p>TIS reduces healthcare costs and improves clinical outcomes compared to CMS in managing BE with PA infections in China. This study supports the inclusion of TIS in clinical guidelines for managing BE with PA infections, considering both economic benefits and health outcomes.<\/jats:p>\n<\/jats:sec>","DOI":"10.1371\/journal.pone.0324254","type":"journal-article","created":{"date-parts":[[2025,6,18]],"date-time":"2025-06-18T17:35:42Z","timestamp":1750268142000},"page":"e0324254","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":0,"title":["Cost-effectiveness analysis of two inhaled antibiotics for stable Bronchiectasis with Pseudomonas aeruginosa infections in China"],"prefix":"10.1371","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7049-9589","authenticated-orcid":true,"given":"Wanxin","family":"Chen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xuerong","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liting","family":"Lai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bin","family":"Hong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Canghong","family":"Zhi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Honglin","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3911-5270","authenticated-orcid":true,"given":"Sha","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jie","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2025,6,18]]},"reference":[{"issue":"1","key":"pone.0324254.ref001","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12931-022-02023-8","article-title":"Increasing prevalence and burden of bronchiectasis in urban Chinese adults, 2013\u20132017: a nationwide population-based cohort study","volume":"23","author":"J Feng","year":"2022","journal-title":"Respir Res"},{"issue":"12","key":"pone.0324254.ref002","doi-asserted-by":"crossref","first-page":"2299","DOI":"10.1007\/s10096-019-03675-z","article-title":"Predicting factors for chronic colonization of Pseudomonas aeruginosa in bronchiectasis","volume":"38","author":"A Pieters","year":"2019","journal-title":"Eur J Clin Microbiol Infect Dis"},{"issue":"7","key":"pone.0324254.ref003","first-page":"1212","article-title":"Bacteriological characteristics and antibiotic sensitivity analysis of 493 cases of acute infection in bronchiectasis","volume":"17","author":"S J","year":"2012","journal-title":"J Clin Pulm Med"},{"key":"pone.0324254.ref004","author":"L Xue","year":"2014"},{"key":"pone.0324254.ref005","article-title":"British Thoracic Society guideline for non-CF bronchiectasis","author":"MC Pasteur","year":"2010","journal-title":"Thorax"},{"issue":"3","key":"pone.0324254.ref006","doi-asserted-by":"crossref","DOI":"10.1378\/chest.1834963","article-title":"Morbidity and risk factors for mortality in patients with acute exacerbation of bronchiectasis","volume":"145","author":"MJ Oliveira","year":"2014","journal-title":"Chest"},{"issue":"3","key":"pone.0324254.ref007","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1016\/j.rmed.2011.11.018","article-title":"Outcomes of Pseudomonas eradication therapy in patients with non-cystic fibrosis bronchiectasis","volume":"106","author":"L White","year":"2012","journal-title":"Respir Med"},{"issue":"3","key":"pone.0324254.ref008","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00629-2017","article-title":"European respiratory society guidelines for the management of adult bronchiectasis","volume":"50","author":"E Polverino","year":"2017","journal-title":"Eur Respir J"},{"issue":"10","key":"pone.0324254.ref009","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1016\/S2213-2600(19)30185-7","article-title":"The efficacy and safety of inhaled antibiotics for the treatment of bronchiectasis in adults: a systematic review and meta-analysis","volume":"7","author":"IF Laska","year":"2019","journal-title":"Lancet Respir Med"},{"issue":"14","key":"pone.0324254.ref010","first-page":"2107","article-title":"Application status and prospect of inhaled antibiotics in bronchiectasis","volume":"39","author":"L Xuedong","year":"2023","journal-title":"Chin J Clin Pharmacol"},{"issue":"1","key":"pone.0324254.ref011","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.chest.2022.07.007","article-title":"A Double-Blind Randomized Placebo-Controlled Phase 3 Trial of Tobramycin Inhalation Solution in Adults With Bronchiectasis With Pseudomonas aeruginosa Infection","volume":"163","author":"W-J Guan","year":"2023","journal-title":"Chest"},{"issue":"05","key":"pone.0324254.ref012","first-page":"2545","article-title":"Clinical experience in treating stable-stage bronchiectasis with inhalation therapy of polymyxin","volume":"29","author":"H Yuzhen","year":"2016","journal-title":"J Contemp Clin Med"},{"issue":"6","key":"pone.0324254.ref013","first-page":"706","article-title":"Efficacy of nebulized antibacterial therapy for acute exacerbations of bronchiectasis with Pseudomonas aeruginosa infection","volume":"44","author":"D Wenjing","year":"2024","journal-title":"Int J Respir"},{"issue":"4","key":"pone.0324254.ref014","first-page":"311","article-title":"Expert consensus on the diagnosis and treatment of adult bronchiectasis in China","volume":"44","author":"Bronchiectasis Expert Consensus Writing Group, Pulmonary Infection Assembly, Chinese Thoracic Society","year":"2021","journal-title":"Zhonghua Jie He He Hu Xi Za Zhi"},{"key":"pone.0324254.ref015","volume-title":"China guidelines for pharmacoeconomic evaluations","author":"C Association","year":"2020"},{"key":"pone.0324254.ref016","article-title":"Eradication treatment in non cf bronchiectasis: The effect of inhaled antibiotics (tobramycin and colistin) on patients with pseudomonas aeruginosa","author":"M Kaponi","year":"2017","journal-title":"Eur J Intern Med"},{"issue":"9","key":"pone.0324254.ref017","article-title":"Head-to-head trials of antibiotics for bronchiectasis","volume":"9","author":"A Kaehne","year":"2018","journal-title":"Cochrane Database Syst Rev"},{"issue":"3","key":"pone.0324254.ref018","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2016-014613","article-title":"Pseudomonas aeruginosa isolation in patients with non-cystic fibrosis bronchiectasis: a retrospective study","volume":"8","author":"H Wang","year":"2018","journal-title":"BMJ Open"},{"issue":"7","key":"pone.0324254.ref019","doi-asserted-by":"crossref","first-page":"556","DOI":"10.47102\/annals-acadmedsg.202178","article-title":"Heterogeneity of non-cystic-fibrosis bronchiectasis in multiethnic Singapore: A prospective cohort study at a tertiary pulmonology centre","volume":"50","author":"SL Young","year":"2021","journal-title":"Ann Acad Med Singap"},{"key":"pone.0324254.ref020","volume-title":"China statistical yearbook 2021","author":"Statistics NBo","year":"2021"},{"issue":"2","key":"pone.0324254.ref021","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1592\/phco.31.2.146","article-title":"Outpatient treatment of Pseudomonas aeruginosa bronchial colonization with long-term inhaled colistin, tobramycin, or both in adults without cystic fibrosis","volume":"31","author":"D Berlana","year":"2011","journal-title":"Pharmacotherapy"},{"issue":"21","key":"pone.0324254.ref022","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.21037\/atm-20-4873","article-title":"Factors associated with bronchiectasis in Korea: a national database study","volume":"8","author":"B Yang","year":"2020","journal-title":"Ann Transl Med"},{"key":"pone.0324254.ref023","volume-title":"Final report on the disease burden of bronchiectasis","author":"B Consulting","year":"2023"},{"issue":"1","key":"pone.0324254.ref024","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1186\/s12931-021-01729-5","article-title":"Risk factors for Pseudomonas aeruginosa colonization in non-cystic fibrosis bronchiectasis and clinical implications","volume":"22","author":"WC Kwok","year":"2021","journal-title":"Respir Res"},{"key":"pone.0324254.ref025","unstructured":"Mengyuan Z. Investigation on the current situation of bronchiectasis in China. The 24th National Conference of Internal Medicine, Chinese Medical Association. 2023."},{"issue":"2","key":"pone.0324254.ref026","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/j.rmed.2013.12.015","article-title":"Mortality in non-cystic fibrosis bronchiectasis: a prospective cohort analysis","volume":"108","author":"PC Goeminne","year":"2014","journal-title":"Respir Med"},{"issue":"7","key":"pone.0324254.ref027","doi-asserted-by":"crossref","DOI":"10.1016\/j.jval.2014.08.1799","article-title":"A De-Novo Economic Model to Assess Clinical and Economic Consequences of Bronchiectasis","volume":"17","author":"SB Bhattacharyya","year":"2014","journal-title":"Value Health"},{"key":"pone.0324254.ref028","unstructured":"Coomarasamy C. Cost-effectiveness and cost-utility analysis of tiotropium treatment for bronchiectasis: evidence from a crossover randomised trial [Thesis]: Auckland University of Technology; 2018."}],"container-title":["PLOS One"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0324254","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,18]],"date-time":"2025-06-18T17:35:52Z","timestamp":1750268152000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0324254"}},"subtitle":[],"editor":[{"given":"Ravi Papu","family":"Manglani","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2025,6,18]]},"references-count":28,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2025,6,18]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0324254","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,18]]}}}